Search

Vir Biotechnology Inc

Gesloten

SectorGezondheidszorg

11.11 -3.22

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.3

Max

11.75

Belangrijke statistieken

By Trading Economics

Inkomsten

206M

80M

Verkoop

239M

239M

EPS

0.47

Winstmarge

33.514

Werknemers

367

EBITDA

201M

78M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+83.5% upside

Dividenden

By Acuity

Volgende Winsten

4 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

492M

2B

Vorige openingsprijs

14.33

Vorige sluitingsprijs

11.11

Nieuwssentiment

By Acuity

50%

50%

133 / 340 Rangschikking in Healthcare

Vir Biotechnology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 okt 2026, 20:07 UTC

News
Social Media

Vir Biotechnology's shares fell following the announcement of David Liu as Chief Medical Officer, despite HC Wainwright reaffirming a Buy rating with a $22 price target.

6 okt 2026, 20:40 UTC

Vir Biotechnology Inc has advanced in after-market trading, rebounding from earlier lows and achieving its highest cumulative return since Tuesday's close.

5 okt 2026, 20:01 UTC

Vir Biotechnology Inc is trading sharply higher, reaching a cumulative return of nearly 6%, near the upper end of its one-month trading range.

2 okt 2026, 20:07 UTC

Vir Biotechnology Inc shares fell sharply, continuing a decline from Thursday's close, despite rebounding earlier in the session.

1 okt 2026, 20:13 UTC

Vir Biotechnology Inc is advancing in after-market trading, holding steady above its 20-day moving average with a cumulative return since Thursday's close.

30 sep 2026, 22:56 UTC

Vir Biotechnology Inc traded modestly lower in after-market hours, continuing a downward trend since Wednesday's close, despite remaining above its 20-day moving average.

29 sep 2026, 20:02 UTC

News

Vir Biotechnology is advancing after partnering with Astellas, securing $335 million to enhance its PRO-XTEN platform and support its Phase 3 hepatitis delta program.

25 sep 2026, 19:55 UTC

Vir Biotechnology Inc shares fell, continuing a decline over the past three sessions, and remain below Thursday's close and the 20-day moving average.

24 sep 2026, 20:07 UTC

Vir Biotechnology Inc's shares are declining, continuing a downward trend since Wednesday, amid notable selling pressure and unfavorable broader market conditions.

23 sep 2026, 20:31 UTC

Vir Biotechnology Inc experienced a notable decline in after-market trading, reaching a low and positioned around the middle of its one-month trading range.

22 sep 2026, 23:31 UTC

Vir Biotechnology Inc has seen a significant decline during after-market trading, with volatility indicating a sharp downturn since Tuesday's close.

21 sep 2026, 20:31 UTC

Vir Biotechnology Inc has advanced in after-market trading, reaching its highest cumulative return since Monday's close and positioned above its 20-day moving average.

18 sep 2026, 19:55 UTC

Vir Biotechnology Inc shares fell sharply, reaching their lowest point around midday and remaining notably below the 20-day moving average.

17 sep 2026, 20:07 UTC

Correlated Moves

Vir Biotechnology is higher amid a biotech sector rally, supported by the SPDR S&P Biotech ETF's rise following Moderna's positive cancer vaccine results.

16 sep 2026, 23:06 UTC

Vir Biotechnology Inc is trading modestly higher during after-market hours, continuing a routine pattern with limited fluctuations since Wednesday's close.

15 sep 2026, 23:41 UTC

Vir Biotechnology Inc shares are lower in after-market hours, following a broader market decline linked to a drop in the New York Empire State Manufacturing Index.

14 sep 2026, 20:13 UTC

Vir Biotechnology Inc shares are higher in after-market hours, continuing a trend of three consecutive sessions in the same direction. No specific news was identified.

11 sep 2026, 20:08 UTC

Vir Biotechnology Inc shares are higher during Friday's session, reflecting broader market trends. The stock experienced volatility, reaching a high shortly after the open.

9 sep 2026, 20:07 UTC

Vir Biotechnology Inc shares are lower today, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

3 sep 2026, 19:46 UTC

Vir Biotechnology Inc shares are lower during Thursday's session, reversing early gains amid significant volatility. No specific news was identified to explain the decline.

2 sep 2026, 23:16 UTC

Vir Biotechnology shares are lower in after-market trading, despite strong one-month performance. The stock remains above its 20-day moving average.

1 sep 2026, 22:06 UTC

Social Media

Vir Biotechnology Inc. has a market cap of $1.6 billion and cash of $1 billion. Shares are higher in after-market trading following recent strong performance.

28 aug 2026, 20:08 UTC

Vir Biotechnology Inc shares are lower today, continuing a decline since Thursday amid rising U.S. Treasury yields and broader market pressures.

27 aug 2026, 20:08 UTC

Vir Biotechnology Inc shares are higher, reflecting a steady upward trend since Wednesday. Broader market conditions may be contributing to this positive movement.

26 aug 2026, 20:08 UTC

Vir Biotechnology Inc is higher in Wednesday's session, continuing its upward trend since Tuesday's close, despite earlier fluctuations in price.

25 aug 2026, 20:09 UTC

Social Media

Vir Biotechnology is gaining as social media discussions highlight its $1 billion cash position and potential catalysts, despite earlier session pullbacks.

24 aug 2026, 21:01 UTC

Vir Biotechnology Inc. shares are trading higher in after-market hours, continuing a recent upward trend amid a rebound in the bond market and lower Treasury yields.

21 aug 2026, 20:02 UTC

Correlated Moves

Vir Biotechnology Inc. shows upward momentum, reflecting significant gains since Thursday's close, amid positive trends in the healthcare sector and broader biotechnology market.

20 aug 2026, 20:02 UTC

Correlated Moves

Vir Biotechnology Inc. shares are trading lower amid a significant decline in the biotechnology sector, influenced by broader market trends and ETF performance.

19 aug 2026, 23:06 UTC

Correlated Moves

Vir Biotechnology Inc's shares are higher in after-market trading, continuing a positive trend and maintaining a position above their 20-day moving average.

Peer Vergelijking

Prijswijziging

Vir Biotechnology Inc Prognose

Koersdoel

By TipRanks

83.5% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 21.286 USD  83.5%

Hoogste 30 USD

Laagste 15 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vir Biotechnology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

8

Buy

0

Hold

0

Sell

Sentiment

By Acuity

133 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.